查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1178083

血栓溶解劑的全球市場:各類型，各用途，各流通管道，各地區─產業規模，佔有率，趨勢，競爭，機會，預測，競爭(2017年～2027年)

Clot Buster Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Type, By Application, By Distribution Channel, By Region
出版日期: | 出版商: TechSci Research | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球血栓溶解劑的市場規模在預測期間(2023年～2027年)中預計將以驚人的年複合成長率成長。

對可立即應對心髒病發作和中風的有效藥物的需求激增、心血管疾病患病率增加以及缺血性中風風險上升正在推動市場增長。

本報告提供全球血栓溶解劑市場相關調查分析，提供產品概要，市場展望，競爭情形等系統性資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 COVID-19對全球血栓溶解劑市場帶來的影響

第4章 摘要整理

第5章 VOC (客戶的迴響)

  • 偏好:各藥物類型
  • 促成凝血藥物需求增加的因素
  • 採用凝塊破壞藥物的障礙
  • 品牌認知度

第6章 臨床試驗

  • 進行中的臨床試驗
  • 完成的臨床試驗
  • 中斷的臨床試驗
  • 臨床試驗分析

第7章 專利分析

  • 取得專利的(2016年～2020年)
  • 專利申請

第8章 全球血栓溶解劑市場展望

  • 市場規模與預測
    • 各金額
  • 市場佔有率與預測
    • 各類型(纖維蛋白特異性藥物，非纖維蛋白特異性藥物)
    • 各用途(心肌梗塞，肺動脈栓塞，深部靜脈血栓症，急性缺血性腦中風，其他)
    • 各流通管道(零售藥局，醫院藥局，線上藥局)
    • 各企業(2021年)
    • 各地區
  • 產品市場地圖

第9章 北美的血栓溶解劑市場展望

第10章 歐洲的血栓溶解劑市場展望

第11章 亞太地區的血栓溶解劑市場展望

第12章 南美的血栓溶解劑市場展望

第13章 中東及非洲的血栓溶解劑市場展望

第14章 市場動態

  • 促進因素
  • 課題

第15章 市場趨勢與開發

第16章 競爭情形

  • F. Hoffmann-La Roche AG
  • Taj Pharmaceuticals Limited
  • Eumedica Pharmaceuticals SA
  • SEDICO Pharmaceutical Company
  • Mochida Pharmaceutical Co., Ltd
  • Medac GmbH
  • Microbix Biosystems Inc
  • Crinos S.p.A.

第17章 策略性建議

第18章 關於本公司·免責聲明

簡介目錄
Product Code: 8207

Global clot buster drugs market is anticipated to grow with an impressive CAGR value in the mentioned forecast years 2023-2027 on the account of increasing instances of heart attacks and strokes. Surge in the demand for the effective pharmaceuticals for the immediate response to heart attacks and strokes is further driving the growth of the global clot buster drugs market in the upcoming five years.

Clot buster drugs are the heart diseases dugs that help in dissolving the blood clots in case of blockage in the veins, that are often cause of strokes and heart attack. Clot buster drugs are also known as thrombolytic therapeutics that are a class of heart medications that are often administered under supervisions in the hospitals through an intravenous injection. Use of these drugs helps in preventing ongoing damage to the heart during heart attack or deteriorating condition due to ischemic stroke. These drugs are also utilized in case the clots are formed in other parts of the blood vessels in the body. Side-effects of these drugs include excessive blood loss from injuries or cuts, allergic reaction to the clot buster drugs, low blood pressure, unusual bleeding in urine, stool etc. thus concerned and monitored administration is a necessity.

Cardiovascular Diseases Drive Market Growth

Increasing instances of cardiovascular diseases are driving the growth of the global clot buster drugs market in the upcoming five years. Rapidly increasing instances of heart attacks, and strokes is also supporting the growth of the global clot buster drugs market in the next five years. Stroke is the 5th leading cause of death in the United States. Increasing instances of strokes demands for the immediate response to the situation where clot buster drugs can help the situation and dissolve the blood clot pooling in the veins thus creating lower blood pressure. Mortality rate among the population is increasing due to strokes and further aiding the growth of the global clot buster drug market. Death rate from stroke among men in the United States is 37.6 per 100,000 population and that in females is 36.1 per 100,000 population.

Also, increasing risks of ischemic strokes among the global population is further substantiating the growth of the global clot buster drugs market in the next five years. The prevalence of ischemic stroke in women was slightly higher than that in men in 2017. In total, there were 82.42 million people who had experienced an ischemic stroke of which 41.81 million were women and 40.61 were men.

Market Segmentation

The global clot buster drugs market segmentation is based on type, application, distribution channel, regional distribution, and competitive landscape. Based on type, the market is divided between fibrin specific drugs and non-fibrin specific drugs. Further segmentation of fibrin specific drug is defined into tissue plasminogen activator, Reteplase, Tenecteplase, and others. Whereas non-fibrin specific drugs are differentiated into urokinase, streptokinase, and plasminogen activating complex. Based on application, the market is further segmented into myocardial infarction, pulmonary embolism, deep vein thrombosis, acute ischemic strokes, and others. Distribution channel segment of the market is also fragmented into retail pharmacies, hospital pharmacies, and online pharmacies. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

F. Hoffmann-La Roche AG, Taj Pharmaceuticals Limited, Eumedica Pharmaceuticals SA, SEDICO Pharmaceutical Company, Mochida Pharmaceutical Co., Ltd, Medac GmbH, Microbix Biosystems Inc, Crinos S.p.A., are enlisted in a partial list of major market players of the global clot buster drugs market. The existing market players are highly invested in research and product development along with viable service provisions for the consumers. New market entrants may follow similar strategies along with merger and acquisition methods for future brand establishment.

Report Scope:

In this report, global clot buster drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Clot Buster Drugs Market, By Type:

Fibrin Specific Drugs

  • Tissue Plasminogen Activator
  • Reteplase
  • Tenecteplase
  • Others

Non-Fibrin Specific Drugs

  • Urokinase
  • Streptokinase
  • Plasminogen Activating Complex
  • Clot Buster Drugs Market, By Application:

Myocardial Infarction

Pulmonary Embolism

Deep Vein Thrombosis

Acute Ischemic Strokes

Others

  • Clot Buster Drugs Market, By Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

  • Clot Buster Drugs Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global clot buster drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Clot Buster Drugs Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Preference, By Drug Type
  • 5.2. Factors Contributing to Higher Demand of Clot Buster Drugs
  • 5.3. Barriers to Adoption of Clot Buster Drugs
  • 5.4. Brand Awareness

6. Clinical Trials

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Clinical Trial Analysis

7. Patent Analysis

  • 7.1. Patent Granted (2016-2020)
  • 7.2. Patent Applications Filed

8. Global Clot Buster Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 8.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 8.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 8.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 8.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 8.2.4. By Company (2021)
    • 8.2.5. By Region
  • 8.3. Product Market Map

9. North America Clot Buster Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 9.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 9.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 9.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 9.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 9.2.4. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Clot Buster Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Mexico Clot Buster Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Canada Clot Buster Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Distribution Channel

10. Europe Clot Buster Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 10.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 10.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 10.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 10.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 10.2.4. By Country
  • 10.3. Europe: Country Analysis
    • 10.3.1. France Clot Buster Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Germany Clot Buster Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. United Kingdom Clot Buster Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Distribution Channel
    • 10.3.4. Italy Clot Buster Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Application
        • 10.3.4.2.3. By Distribution Channel
    • 10.3.5. Spain Clot Buster Drugs Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By Application
        • 10.3.5.2.3. By Distribution Channel

11. Asia-Pacific Clot Buster Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 11.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 11.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 11.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 11.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 11.2.4. By Country
  • 11.3. Asia-Pacific: Country Analysis
    • 11.3.1. China Clot Buster Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Application
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. India Clot Buster Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Application
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. South Korea Clot Buster Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Application
        • 11.3.3.2.3. By Distribution Channel
    • 11.3.4. Japan Clot Buster Drugs Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Type
        • 11.3.4.2.2. By Application
        • 11.3.4.2.3. By Distribution Channel
    • 11.3.5. Australia Clot Buster Drugs Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Type
        • 11.3.5.2.2. By Application
        • 11.3.5.2.3. By Distribution Channel

12. South America Clot Buster Drugs Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 12.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 12.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 12.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 12.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 12.2.4. By Country
  • 12.3. South America: Country Analysis
    • 12.3.1. Brazil Clot Buster Drugs Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Type
        • 12.3.1.2.2. By Application
        • 12.3.1.2.3. By Distribution Channel
    • 12.3.2. Argentina Clot Buster Drugs Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Type
        • 12.3.2.2.2. By Application
        • 12.3.2.2.3. By Distribution Channel
    • 12.3.3. Colombia Clot Buster Drugs Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Type
        • 12.3.3.2.2. By Application
        • 12.3.3.2.3. By Distribution Channel

13. Middle East and Africa Clot Buster Drugs Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value
  • 13.2. Market Share & Forecast
    • 13.2.1. By Type (Fibrin Specific Drugs v/s Non-Fibrin Specific Drugs)
      • 13.2.1.1. By Fibrin Specific Drugs (Tissue Plasminogen Activator, Reteplase, Tenecteplase, Others)
      • 13.2.1.2. By Non-Fibrin Specific Drugs (Urokinase, Streptokinase, Plasminogen Activating Complex)
    • 13.2.2. By Application (Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis, Acute Ischemic Strokes, Others)
    • 13.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 13.2.4. By Country
  • 13.3. MEA: Country Analysis
    • 13.3.1. South Africa Clot Buster Drugs Market Outlook
      • 13.3.1.1. Market Size & Forecast
        • 13.3.1.1.1. By Value
      • 13.3.1.2. Market Share & Forecast
        • 13.3.1.2.1. By Type
        • 13.3.1.2.2. By Application
        • 13.3.1.2.3. By Distribution Channel
    • 13.3.2. Saudi Arabia Clot Buster Drugs Market Outlook
      • 13.3.2.1. Market Size & Forecast
        • 13.3.2.1.1. By Value
      • 13.3.2.2. Market Share & Forecast
        • 13.3.2.2.1. By Type
        • 13.3.2.2.2. By Application
        • 13.3.2.2.3. By Distribution Channel
    • 13.3.3. UAE Clot Buster Drugs Market Outlook
      • 13.3.3.1. Market Size & Forecast
        • 13.3.3.1.1. By Value
      • 13.3.3.2. Market Share & Forecast
        • 13.3.3.2.1. By Type
        • 13.3.3.2.2. By Application
        • 13.3.3.2.3. By Distribution Channel
    • 13.3.4. Egypt Clot Buster Drugs Market Outlook
      • 13.3.4.1. Market Size & Forecast
        • 13.3.4.1.1. By Value
      • 13.3.4.2. Market Share & Forecast
        • 13.3.4.2.1. By Type
        • 13.3.4.2.2. By Application
        • 13.3.4.2.3. By Distribution Channel

14. Market Dynamics

  • 14.1. Drivers
  • 14.2. Challenges

15. Market Trends & Developments

16. Competitive Landscape

  • 16.1. F. Hoffmann-La Roche AG
  • 16.2. Taj Pharmaceuticals Limited
  • 16.3. Eumedica Pharmaceuticals SA
  • 16.4. SEDICO Pharmaceutical Company
  • 16.5. Mochida Pharmaceutical Co., Ltd
  • 16.6. Medac GmbH
  • 16.7. Microbix Biosystems Inc
  • 16.8. Crinos S.p.A.

17. Strategic Recommendations

18. About Us & Disclaimer